Paraneoplastic hypereosinophilia in a dog with intestinal T-cell lymphoma.
A 9-year-old, intact male Doberman Pinscher was examined because of anorexia and weakness. Results of a CBC showed severe, microcytic, hypochromic anemia with mild eosinophilia (2944 cells/microL, reference interval 100-1250/microL) and thrombocytosis. Hypoferremia, hypoferritinemia, and a positive fecal occult blood test supported a diagnosis of iron deficiency anemia secondary to chronic intestinal hemorrhage. Abdominal ultrasound evaluation showed a thickened small intestinal loop, of which representative specimens were obtained during exploratory laparotomy. Histologically, the intestinal wall was infiltrated by a neoplastic population of large, round, lymphoid cells with vesicular chromatin, 1 or more prominent nucleoli, and a high number of mitotic figures. The cells were closely admixed with mature eosinophils, but were negative for metachromatic granules with toluidine blue. Immunohistochemically, tumor cells were positive for CD3, and negative for CD21, Pan B, and CD79a. A diagnosis of intestinal T-cell lymphoma was made. Chemotherapy was begun, with 30 mg/m;2 of doxorubicin administered intravenously every 3 weeks. Eosinophil concentration was 880/microL 2 weeks after surgery (on day 15 after presentation) but increased markedly to 62,914/microL on day 30, 62,400/microL on day 37, and 39,444/microL on day 58 after presentation. An association between hypereosinophilia and T-cell lymphoma is well established in human patients, in whom production of IL-5 by neoplastic T cells has been demonstrated. Hypereosinophilia has been reported only rarely with intestinal lymphoma in cats and horses, and with T-cell lymphoma in dogs.
Marchetti
Veronica
V
Department of Veterinary Clinics, University of Pisa, Italy. v.marchetti@vet.unipi.it
Benetti
Cecilia
C
Citi
Simona
S
Taccini
Valentina
V
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004283:Dog Diseases / Q000097:blood*; D004285:Dogs; D004317:Doxorubicin / Q000627:therapeutic use; D017809:Fatal Outcome; D017681:Hypereosinophilic Syndrome / Q000209:etiology / Q000473:pathology / Q000662:veterinary*; D007414:Intestinal Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D016399:Lymphoma, T-Cell / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D008297:Male; D010257:Paraneoplastic Syndromes / Q000188:drug therapy / Q000209:etiology / Q000473:pathology / Q000662:veterinary*
D000970:Antineoplastic Agents; D004317:Doxorubicin